Published online Jun 30, 2019. doi: 10.13105/wjma.v7.i6.309
Peer-review started: April 15, 2019
First decision: May 16, 2019
Revised: June 4, 2019
Accepted: June 10, 2019
Article in press: June 10, 2019
Published online: June 30, 2019
Pancreatic cancer is one of the most common and lethal malignancies worldwide. The common treatment options for resectable pancreatic cancer include surgery alone, neoadjuvant chemo-therapy (CT), neoadjuvant chemoradiotherapy (CRT), adjuvant CT, and adjuvant CRT. However, the optimal treatment is still controversial.
The optimal treatment for resectable pancreatic cancer is still controversial.
This study aimed to identify the most effective approach for resectable pancreatic cancer using network meta-analysis.
Eligible studies were searched from PubMed, Medline, EMBASE, Cochrane database, and Google scholar. We searched and included randomized controlled trials reporting on neo-adjuvant and adjuvant therapies. For direct comparisons, standard pairwise meta-analysis was performed using the inverse variance DerSimonian-Laird random-effects model. For indirect comparisons, Bayesian network meta-analysis was used to combine direct and indirect evidence. We used relative hazard ratios (HRs) to estimate survival difference between different treat-ments, and relative odds ratios (ORs) for toxic effects. Treatment effects were ranked based on their efficacy for improving survival or reducing toxicity using rankogram. The quality of evidence of estimates from direct comparison and network meta-analysis were evaluated following the GRADE approach.
We included 13 high quality trials with 1591 participants in this network meta-analysis. Com-pared with surgery alone (pooled HR = 0.7, 95%CI: 0.62-0.79) and surgery with adjuvant CRT (pooled HR = 0.6, 95%CI: 0.54-0.72), surgery with adjuvant CT had a higher rate of overall survival. In contrast, standard pairwise meta-analysis only showed a statistically significant survival advantage of surgery with adjuvant CT compared with surgery alone (pooled HR = 0.75, 95%CI: 0.63-0.89; P < 0.001). Rankogram showed that surgery with adjuvant CT was most likely to rank the best in terms of overall survival (probability: 94.2%), followed by surgery alone (probability: 5.8%). No significant differences in overall toxicity or haematological toxicity were found between all the therapies. High quality evidence supported surgery with adjuvant CT over surgery alone for increasing overall survival. Moderate quality evidence supported surgery with adjuvant CT over surgery with adjuvant CRT for increasing overall survival.
Our network meta-analysis show that surgery with adjuvant CT prolongs overall survival compared with surgery alone and surgery with adjuvant CRT.
We recommend surgery with adjuvant CT as the optimal care for resectable pancreatic cancer. Later research should be focused on the best agents for adjuvant CT.